

AMENDMENTS TO THE CLAIMS UNDER REVISED 37 C.F.R. § 1.121

Please cancel Claims 2-3 and 11 without prejudice to their refilling in future continuation applications. Please add Claims 59-61. Please amend the claims as follows:

1. (Currently amended) An isolated nucleic acid molecule comprising:
- (a) the nucleotide sequence as set forth in SEQ ID NO: 1;
 - (b) a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 2 or SEQ ID NO: 3;
 - (c) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of either (a) or (b) at
 - (i) 50-65-68°C in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate or
 - (ii) 42°C in a hybridization buffer comprising 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide; or
 - (d) a nucleotide sequence that is complementary to any one of (a) - (c).

2-3. (Cancelled)

4. (Currently amended) A vector comprising the nucleic acid molecule of any of Claims 1(a) - 1(c), ~~2(a) - 2(e), or 3(a) - (e).~~

5. (Original) A host cell comprising the vector of Claim 4.

6. (Original) The host cell of Claim 5 that is a eukaryotic cell.

7. (Original) The host cell of Claim 5 that is a prokaryotic cell.

8. (Currently amended) A process of producing ~~an LGR8 polypeptide~~ encoded by the nucleic acid molecule of any of Claims 1(a) – 1(c) comprising culturing the host cell of Claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

9. (Original) A polypeptide produced by the process of Claim 8.

10. (Currently amended) The process of Claim 8, wherein the ~~nucleic acid molecule~~ vector comprises promoter DNA other than the native promoter ~~DNA for the native LGR8 polypeptide of~~ SEQ ID NO: 1 operatively linked to the DNA encoding the ~~LGR8~~ polypeptide encoded by the nucleic acid molecule of any of Claims 1(a) – 1(c).

11. (Cancelled)

12. (Currently amended) A process for determining whether a compound inhibits ~~LGR8~~ polypeptide activity or ~~LGR8~~ polypeptide production of a polypeptide encoded by the nucleic acid molecule of any of Claims 1(a) – 1(c) comprising exposing a cell according to any of Claims 5, 6, or 7 to the compound and measuring ~~LGR8~~ the polypeptide activity or ~~LGR8~~ the polypeptide production in said cell.

13-42. (Cancelled)

43. (Currently amended) A composition comprising a nucleic acid molecule of ~~any of~~ Claims 1, ~~2, or 3~~ and a pharmaceutically acceptable formulation agent.

44. (Original) The composition of Claim 43, wherein said nucleic acid molecule is contained in a viral vector.

45. (Currently amended) A viral vector comprising a nucleic acid molecule of ~~any of~~ Claims 1, ~~2, or 3~~.

46-58. (Cancelled)

59. (New) An isolated nucleic acid molecule according to Claim 1 wherein the nucleotide sequence is as set forth in SEQ ID NO: 1.

60. (New) An isolated nucleic acid molecule according to Claim 1 wherein the nucleotide sequence encodes the polypeptide as set forth in SEQ ID NO: 2 or SEQ ID NO: 3.

61. (New) An isolated nucleic acid molecule according to Claim 1 wherein the nucleotide sequence hybridizes to the complement of SEQ ID NO:1 or to the complement of a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 2 or SEQ ID NO: 3 at

(i) 65-68°C in a hybridization buffer comprising 0.015 M sodium chloride and 0.0015 M sodium citrate or

(ii) 42°C in a hybridization buffer comprising 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide.